Last reviewed · How we verify
Standard dose carbamazepine
Carbamazepine, marketed by the Mario Negri Institute for Pharmacological Research, is a well-established anticonvulsant with a strong presence in the treatment of epilepsy and related conditions. The drug's key strength lies in its long-standing use and well-documented efficacy, supported by a key composition patent expiring in 2028. However, the primary risk is the potential increase in competition as the patent expiration approaches, which could erode market share and revenue.
At a glance
| Generic name | Standard dose carbamazepine |
|---|---|
| Also known as | Standard carbamazepine |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060 (PHASE1)
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Efficacy of SMOF Lipid in the Management of Acute Poisoning With Carbamazepine (PHASE2)
- Pharmacokinetics Study on Nevirapine Resistance in Tanzania (PHASE2)
- Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain (PHASE1)
- Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT (PHASE2)
- Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy (PHASE3)
- Efficacy of Combined Treatment for Young Bipolar I Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: